ARON-3 Study: International Multicentric Retrospective Study to Collect Global Experiences in the Treatment of Patients With Metastatic PCa

N/ARecruitingNCT06200558

Hospital of Macerata534 enrolled

Overview

Study wants to explore real-world data in three distinct settings * Patients with metachronous or de novo mCSPC treated with ADT+ARSI or ADT+ARSI+docetaxel \_ARON-3S * Patients receiving Lutetium-177 PSMA for mCRPC \_ ARON-3Lu * Patients treated with PARP inhibitors (alone or combined with ARSI) for CRPC \_ ARON-3GEN

Study Type

OBSERVATIONAL

Enrollment

534

Conditions

Prostate Cancer

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients aged \>18y * Cytological or Histologically confirmed diagnosis of PC * Histologically or radiologically confirmed diagnosis of metastatic disease and For ARON-3S ▪ Treatment with ADT + Apalutamide or ADT + enzalutamide or ADT + Abiraterone or ADT + Abiraterone + Docetaxel or ADT + Darolutamide + Docetaxel (patients treated with previous docetaxel - CHAARTED - resulted eligible) For ARON-3Lu ▪ Treatment with Luthetium-177-PSMA therapy for castration resistant PC For ARON-3GEN * HRD POSITIVE STATUS * Treatment with PARP inhibitors for castration resistant PC. Treatment included: olaparib (as 1st, 2nd or 3rd line therapy), olaparib + abiraterone (as 1st line therapy) or niraparib + abiraterone (as 1st line therapy) or talazoparib + enzalutamide Exclusion Criteria: * Patients without histologically confirmed diagnosis of PC * Patients without histologically or radiologically confirmed metastatic disease and For ARON-3S ▪ Patients treated with doublets or triplets not included in the list reported in the Inclusion Criteria Section For ARON-3Lu ▪ Patients treated with Luthetium-177-PSMA therapy for hormone/castration sensitive PC For ARON-3GEN * HRD NEGATIVE STATUS * Patients treated with PARP inhibitors alone or in combination regimens not included in the ARON-3GEN study

Locations (1)

Ospedale di Macerata

Province of Macerata, Macerata, Italy

RECRUITING

Outcomes

Primary Outcomes

Overall Survival (OS) of patients with hormone/castration-sensitive PC treated with ADT + ARSI or ADT + ARSI + docetaxel